With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1104083-27-3,tert-Butyl 3-hydroxy-3-methylpiperidine-1-carboxylate,as a common compound, the synthetic route is as follows.
Into a 250-mL round-bottomed flask, was placed tert-butyl 3-hydroxy-3- methylpiperidine-l-carboxylate (3 g, 13.9 mmol, 1 eq.), DCM (60 mL), pyridine (2.2 g, 0.03 mmol, 2 eq.). This was followed by the addition of a solution of 4-nitrophenyl carbonochloridate (8.4 g, 0.04 mmol, 3 eq.) in DCM (30 mL) dropwise with stirring at 0 C. The resulting solution was stirred for 3 days at rt. The reaction was then quenched by the addition of water (50 mL). The resulting mixture was washed with H2O (1 x 50 mL). The mixture was dried over anhydrous sodium sulfate and concentrated. The residue was applied onto a silica gel column with ethyl acetate :petroleum ether (10:90). This resulted in 2.5 g (47.16%) of tert-butyl 3-methyl-3-[[(4-nitrophenoxy)carbonyl]oxy]piperidine-l-carboxylate as a colorless oil.
1104083-27-3, As the paragraph descriping shows that 1104083-27-3 is playing an increasingly important role.
Reference:
Patent; PRINCIPIA BIOPHARMA INC.; LOU, Yan; OWENS, Timothy Duncan; BRAMELD, Kenneth Albert; GOLDSTEIN, David Michael; (302 pag.)WO2019/99582; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem